Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation ...
A major UK clinical trial has shown that adding the corticosteroid dexamethasone to standard antiviral treatment for encephalitis (brain inflammation), caused by herpes simplex virus (HSV) does not ...
Herpes simplex virus (HSV) encephalitis, caused by HSV types 1 and 2, is the most common sporadic viral encephalitis worldwide, with an annual incidence of around 2·2–4·6 per million people.1 Before ...
A major UK clinical trial has shown that adding the corticosteroid dexamethasone to standard antiviral treatment for ...
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a ...
This time, Tecvayli excelled as a solo agent, reducing the risk of disease progression or death by 71% over standard of care in a group of multiple myeloma patients resistant to anti-CD38 therapy.
The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the anti-VEGF group. Visual acuity and central macular thickness improved in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results